Blacksburg biotech company Landos Biopharma Inc. has gone public.
An initial public offering of stock, priced at $16 a share, was expected to raise $100 million to develop possible new treatments for autoimmune diseases.
The Landos labs at the Virginia Tech Corporate Research Center have “identified seven novel immunometabolic targets and product candidates” for the treatment of such ailments as ulcerative colitis, Crohn’s disease, lupus, rheumatoid arthritis, multiple sclerosis, Alzheimer’s disease, asthma, psoriasis, chronic obstructive pulmonary disease and type 1 diabetes.
Those descriptions and scores of scientific charts have been filed by Landos with the U.S. Securities and Exchange Commission.
Click here to read more via The Roanoke Times.
Latest posts by BioBuzz Media (see all)
- Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B - September 14, 2021
- Ariel Gruswitz, JD, Joins Facility Logix as Associate Director - September 14, 2021
- USP launches an Office of Organizational Culture, Equity and Inclusion Excellence headed by Chief Equity Officer and Senior Advisor Debra Joy Pérez, Ph.D. - September 13, 2021
- Boyds Opens US Office in Philadephia Area - September 13, 2021
- AbbVie and Rockville’s REGENXBIO Announce Eye Care Collaboration - September 13, 2021